IL-23-TF tag mRNA-LNP

The IL-12beta (IL-12p40) subunit is encoded by the IL-12B gene and the IL-23alpha (IL-23p19) subunit is encoded by the IL-12A gene. As a disulfide-linked complex with the polypeptide p19 binding protein p40, IL-23 is mainly secreted by activated macrophages and dendritic cells located in peripheral tissues. The IL-23 receptor is also a heterodimer of IL-12Rβ1 and IL-23R: the p19 subunit binds IL-23R, while the p40 subunit binds IL-12Rβ1. By binding to the receptor, IL-23 triggers its downstream signaling cascade. Much like IL-12, IL-23 has been implicated in several autoimmune inflammatory diseases, such as colitis, gastritis, psoriasis, and arthritis. However, based on the discovery of p19 and p40 but not IL-12alpha (p35) mRNA, IL-23, rather than IL-12, is the primary cytokine controlling inflammation in peripheral tissues and joints. In addition, IL-23 has been used as one of the therapeutic targets for the treatment of inflammatory diseases. This product is designed as a tool for the delivery and expression of TF-tagged human IL23 mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of hIL23-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The hIL23-TF protein is about 61 kD, consisting of IL-12beta (p40) and IL-23alpha (p19) with 15aa linker GGGGSGGGGSGGGGS between them and with a C-terminal TF tag (15 amino acids). GenPept accession numbers of human IL-12beta (p40) and IL-23alpha (p19) are NP_002178 and NP_057668.